Industry Insights: Healthcare
In this year’s first round of #healthcare insights, we highlight a much anticipated drug approval and two recent findings in the healthcare industry.
FDA approves the first GLP-1 pill for obesity treatment
The US Food and Drug Administration (FDA) has approved the first once-daily oral semaglutide (Wegovy; Novo Nordisk) pill. This approval marks a milestone in obesity care. In the OASIS 4 trial, patients achieved substantial weight loss when oral semaglutide was combined with lifestyle counselling, with a safety profile consistent with injectable GLP-1 therapies. According to the trial, the oral formulation may improve accessibility and long-term adherence, particularly for patients reluctant to injections. With additional oral GLP-1 candidates in development, competition in this space is expected to intensify.
Link to press release: https://shorturl.at/A2qdu
RSV vaccination shows clear benefit in older adults
A large systematic review has backed the clinical value of prefusion F (preF) protein RSV (respiratory syncytial virus) vaccines in adults aged 60 years and older. RSV is a respiratory illness that usually causes cold-like symptoms. The review involved almost 100,000 participants and found that vaccination significantly reduced lower respiratory tract infections and RSV-associated acute respiratory illness compared with placebo. Safety findings were also reassuring. The vaccines showed higher rates of mild injection-site reactions but no increase in serious adverse events.
Link to study: https://shorturl.at/ZKp5K
Sleep apnea is a modifiable risk factor for Parkinson’s disease
Evidence from a study involving over 11 million US veterans suggested that obstructive sleep apnea (OSA) is associated with a modest but significant increase in Parkinson’s disease risk. OSA is a common sleep disorder in which breathing repeatedly stops and starts because of upper airway collapse or blockage during sleep. Importantly, early treatment with continuous positive airway pressure (CPAP) was linked to fewer Parkinson’s disease cases. The findings position OSA as a potentially modifiable risk factor with meaningful implications for long-term brain health.
Link to study: https://shorturl.at/nljYa
For more industry insights visit elion.nz/insights/
Want to get in touch? Contact us today at https://elion.nz/get-in-touch/.
